Last year Lilly sold $2.8 Billion worth of Humalog, while Novo Nordisk sold $2.6 Billion of Novolog. Yet Lilly sold $4.1 Billion worth of Trulicity while Novo’s GLP-1 franchise which includes Victoza and Ozempic had combined sales of $4.9 Billion. Throw in sales of Basaglar $1.1 Billion and $3 Billion for Novo’s long acting insulin’s and a picture emerges. A picture which says while these companies may be known for insulin however they are no longer insulin first companies. A fact that will only get reinforced when we have multiple short . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.